Summit Therapeutics SMMT
NASDAQ SMMT
$17.60 +0.48 (+2.77%)
As of: Sep 4, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Profit After Tax (QoQ) (2017 - 2026)

Analysis

Summit Therapeutics (SMMT) Profit After Tax (QoQ) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Summit Therapeutics 13.67 Bn 12.98 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.89%
Mar 31, 2026 13.51%
Dec 31, 2025 5.52%
Sep 30, 2025 59.04%
Jun 30, 2025 -799.49%
Mar 31, 2025 -2.79%
Dec 31, 2024 -8.80%
Sep 30, 2024 6.84%
Jun 30, 2024 -38.90%
Mar 31, 2024 -18.48%
Dec 31, 2023 -72.52%
Sep 30, 2023 -34.97%
Jun 30, 2023 97.09%
Mar 31, 2023 -2,878.61%
Dec 31, 2022 15.05%
Sep 30, 2022 -27.80%
Jun 30, 2022 27.58%
Mar 31, 2022 14.55%
Dec 31, 2021 -32.44%
Sep 30, 2021 16.19%